5th LNP Formulation and Process Development Summit

LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers Squibb/Orbital Therapeutics. V_a_l_i_d_a_t_i_n_g LNPs as a stand-out delivery vehicle for cell and gene therapies!

Returning to Boston in April 2026, the 5th LNP Formulation and Process Development Summit is an industry-led end-to-end meeting providing the latest scientific content to advance LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. This is your one-stop shop to hear insights on LNP discovery, analytics, formulation, process development and large-scale manufacturing.

With 3 focused streams, Analytical Development and Characterization, Formulation and Delivery and Process Development and Manufacturing, this is your opportunity to overcome challenges in achieving precise extrahepatic delivery, robust characterization of targeted LNPs and optimal formulations for ambient storage, all towards making LNP drug products more selective, safe and potent.

Uniting 250+ global LNP trailblazers, gain exclusive access to LNP specific networking, partnership opportunities and collaborative discussions to drive the next-generation of LNPs towards the clinic.